Related by context. All words. (Click for frequent words.) 77 enzastaurin 75 iniparib 75 sorafenib Nexavar 75 temsirolimus 75 mapatumumab 75 sunitinib malate 75 pomalidomide 74 phase IIb clinical 74 BAY #-# 74 ganetespib 74 metastatic renal cell carcinoma 74 PXD# 73 pertuzumab 73 vandetanib 73 HER2 positive metastatic breast 73 cediranib 73 neratinib 73 HGS ETR2 73 elotuzumab 73 tremelimumab 72 sunitinib 72 glufosfamide 72 BRAF inhibitor 72 lintuzumab 72 ixabepilone 72 figitumumab 72 Phase Ib clinical 72 Aplidin 72 ASA# 72 abiraterone acetate 72 Aflibercept 72 T DM1 72 YONDELIS 72 TORISEL 72 standard chemotherapy regimen 72 teriflunomide 72 HGS# 72 entinostat 71 evaluating tivozanib 71 bendamustine 71 Targretin 71 sorafenib 71 Nexavar sorafenib 71 HuMax EGFr 71 regorafenib 71 Amrubicin 71 alvespimycin 71 afatinib 71 docetaxel chemotherapy 71 elacytarabine 71 FTY# 71 adecatumumab 71 oral ridaforolimus 71 eltrombopag 71 INCB# [001] 71 docetaxel Taxotere ® 71 pazopanib 71 Carfilzomib 71 docetaxel Taxotere R 70 phase IIa clinical 70 relapsed refractory multiple myeloma 70 crizotinib PF # 70 Ceflatonin 70 olaparib 70 HGS ETR1 70 CoFactor 70 IMC A# 70 amrubicin 70 phase IIa 70 heavily pretreated 70 CA4P 70 EndoTAG TM -1 70 AEGR 70 Zybrestat 70 JAK inhibitor 70 metastatic castration resistant 70 SUTENT 70 tanespimycin 70 cetuximab Erbitux 70 lumiliximab 70 antitumor activity 70 Phase Ib study 70 tesmilifene 70 radiation sensitizer 70 riociguat 70 Tarceva erlotinib 70 ToGA 70 zalutumumab 70 Torisel 70 Phase 2a trial 70 ZACTIMA 69 Phase IIIb clinical 69 cytokine refractory 69 IMGN# 69 HRPC 69 forodesine 69 bosutinib 69 erlotinib Tarceva ® 69 Telcyta 69 lapatinib Tykerb 69 ZOLINZA 69 IMA# 69 Tarceva TM 69 vorinostat 69 Phase Ib II 69 OncoVEX GM CSF 69 mRCC 69 aflibercept 69 vismodegib 69 LAF# 69 gemcitabine carboplatin 69 ocrelizumab 69 PEG SN# 69 PSMA ADC 69 MAGE A3 ASCI 69 abiraterone 69 Phenoptin 69 HuMax CD# 69 LymphoStat B 69 darapladib 69 sapacitabine 69 panitumumab Vectibix 69 Phase Ib 69 cilengitide 69 ongoing Phase 1b 69 EOquin TM 69 Phase 1b 69 dacetuzumab 69 phase Ib 69 LUX Lung 69 Cloretazine 69 gemcitabine chemotherapy 69 sunitinib Sutent 69 Fludara 69 Allovectin 7 ® 69 ZYBRESTAT 69 Bezielle 69 cabazitaxel 69 sorafenib Nexavar ® 69 vidofludimus 69 XmAb# 69 trabectedin 69 recurrent NSCLC 69 TELCYTA 69 vemurafenib 69 phase IIb 69 vicriviroc 69 rNAPc2 68 decitabine 68 pegylated liposomal doxorubicin 68 RG# [001] 68 PF # [001] 68 AP# [003] 68 deforolimus 68 Tyrima 68 nab paclitaxel 68 Phase 2b trial 68 metastatic HRPC 68 anti leukemic 68 relapsed MM 68 bevacizumab Avastin 68 carboplatin paclitaxel 68 gefitinib Iressa 68 Taxotere chemotherapy 68 MGd 68 SCH # 68 tafamidis 68 Vitaxin 68 depsipeptide 68 Dacogen injection 68 obatoclax 68 phase IIb trial 68 Imprime PGG 68 Sorafenib 68 placebo controlled clinical 68 mertansine 68 carfilzomib 68 huC# DM4 68 Erbitux cetuximab 68 azacitidine 68 tocilizumab 68 dose escalation clinical 68 Axitinib 68 mTOR inhibitor 68 apremilast 68 TTF Therapy 68 Cloretazine ® 68 Phase IIb trials 68 custirsen 68 Azedra 68 Revlimid lenalidomide 68 refractory CLL 68 XL# [003] 68 PROSTVAC TM 68 ruxolitinib 68 Phase 1b trial 68 refractory multiple myeloma 68 phase IIb study 68 ProSavin 68 randomized Phase IIb 68 ASONEP 68 relapsed multiple myeloma 68 metastatic colorectal cancer 68 perifosine 68 Pemetrexed 68 Avastin bevacizumab 68 Onconase 68 Doxil 68 Vandetanib 68 iclaprim 68 Viramidine 67 relapsed ovarian cancer 67 erlotinib 67 SAR# [004] 67 randomized Phase III 67 EndoTAGTM 1 67 interferon gamma 1b 67 Arranon 67 Dasatinib 67 registrational trial 67 TELINTRA 67 Doxil ® 67 sorafenib tablets 67 refractory acute myeloid 67 trastuzumab DM1 67 BRIM3 67 registrational 67 panitumumab 67 midstage clinical 67 Ixempra 67 ponatinib 67 dirucotide 67 Plicera 67 posaconazole 67 mycophenolate mofetil 67 liposomal doxorubicin 67 Phase #/#a trial 67 bortezomib Velcade 67 HuLuc# 67 trastuzumab DM1 T DM1 67 Neuvenge 67 Xanafide 67 multicenter Phase 67 romidepsin 67 Alocrest 67 BRIM2 67 AVADO 67 GVAX 67 IRX 2 67 receptor tyrosine kinase inhibitor 67 thalidomide Thalomid 67 eprotirome 67 eniluracil 67 OvaRex ® MAb 67 angiogenesis inhibitor 67 CIMZIA ™ 67 PTK ZK 67 lupus nephritis 67 GALNS 67 investigational compound 67 anidulafungin 67 Folotyn 67 vascular disrupting agent 67 Traficet EN 67 atacicept 67 PRT# 67 dose escalation Phase 67 docetaxel Taxotere 67 brivaracetam 67 L BLP# 67 Asentar 67 Vectibix 67 oral deforolimus 67 motesanib 67 metaglidasen 67 RSR# 67 trastuzumab Herceptin R 67 Gemzar ® 67 daclizumab 67 Telintra 67 IL# PE#QQR 67 talabostat 67 anti angiogenic therapy 67 Velcade bortezomib 67 galiximab 67 SNT MC# 67 metastatic renal cell 67 gemcitabine Gemzar 67 teduglutide 67 Golimumab 67 Fibrillex TM 67 PSN# [002] 67 TREANDA 67 PEG Interferon lambda 67 PARP inhibitor 67 Archexin 67 recurrent glioblastoma 67 Onrigin 67 Sym# 67 Panzem R NCD 67 ON #.Na 67 cangrelor 67 APOPTONE 67 Jevtana 67 Gleevec imatinib mesylate 67 Taxotere R 67 AVASTIN 67 heavily pretreated patients 67 TG# [003] 67 demonstrated antitumor activity 67 tivozanib 67 Phase IIa trial 67 satraplatin Phase 67 Canvaxin 66 HoFH 66 GAMMAGARD 66 Advexin 66 ipilimumab 66 urocortin 2 66 velafermin 66 ELACYT 66 Reverset 66 platinum refractory 66 cariprazine 66 imatinib Gleevec ® 66 talactoferrin 66 refractory CTCL 66 seliciclib 66 capecitabine Xeloda R 66 Mipomersen 66 metastatic RCC 66 EFAPROXYN 66 FOLFIRI 66 ZD# [001] 66 OHR/AVR# 66 ridaforolimus 66 HuMax CD4 66 Aclidinium 66 Zolinza 66 TACI Ig 66 Nuvion 66 atrasentan 66 indolent NHL 66 mipomersen 66 Allovectin 7 R 66 Quinamed 66 Cloretazine R VNP#M 66 VELCADE melphalan 66 ISIS # 66 oral prodrug 66 visilizumab 66 Exherin TM 66 low dose cytarabine 66 mCRC patients 66 Satraplatin 66 Erlotinib 66 Reolysin 66 plus dexamethasone 66 pharmacokinetic PK study 66 OPAXIO 66 Pazopanib 66 liposomal formulation 66 OXi# 66 severe hypercholesterolemia 66 CYC# 66 investigational humanized monoclonal antibody 66 pemetrexed Alimta 66 CBLC# 66 relapsed SCLC 66 fosbretabulin 66 prostate cancer mCRPC 66 lintuzumab SGN 66 ILLUMINATE 66 dose cohorts 66 APPRAISE 66 otelixizumab 66 Glufosfamide 66 RRMS patients 66 pegylated interferons 66 NVA# 66 CIMZIA TM 66 Phase Ib clinical trials 66 Tavocept 66 Prostate AdenoCarcinoma Treatment 66 Phase 2b study 66 dose escalation trial 66 Taxotere ® 66 Xyotax 66 trastuzumab emtansine T DM1 66 placebo controlled Phase 66 TYKERB 66 bevacizumab 66 PRTX 66 refractory AML 66 CR# vcMMAE 66 multicenter Phase II 66 Virulizin ® 66 zanolimumab 66 RGB # 66 Phase #b/#a clinical 66 GW# [003] 66 Ophena TM 66 TroVax 66 huN# DM1 66 valopicitabine 66 MabCampath 66 lapatinib 66 Genz # 66 sipuleucel T 66 randomized discontinuation trial 66 IMC #B 66 advanced NSCLC 66 Phase 2b clinical 66 recurrent glioblastoma multiforme 66 malignant pleural mesothelioma 66 INCB# [003] 66 PEGylated interferon beta 1a 66 perampanel 66 Rituxan rituximab 66 oral FTY# 66 favorable pharmacokinetic profile 66 Xelox 66 Perifosine 66 Phase 1a clinical 66 MEK inhibitor RDEA# 66 Treanda 66 randomized Phase 66 voreloxin 66 ATL# [001] 66 Azixa 66 ACTEMRA TM 66 UPLYSO 66 tipifarnib 66 Tanespimycin 66 Proxinium TM 66 midstage trials 66 XL# SAR# 66 Randomized Phase 66 ofatumumab 65 lorvotuzumab mertansine 65 randomized Phase 2b 65 viral kinetic 65 Nexavar ® 65 MGCD# [001] 65 oxaliplatin Eloxatin 65 metastatic hormone refractory 65 proteasome inhibitor 65 paclitaxel Taxol ® 65 HQK 65 anticancer agent 65 compound INCB# 65 TOCOSOL Paclitaxel 65 PI3K/Akt pathway inhibitor 65 Seliciclib 65 HCV SPRINT 65 Ceplene/IL-2 65 AEG# 65 IMPACT IMmunotherapy 65 MDV# 65 Phase 1b clinical 65 randomized multicenter Phase III 65 Nexavar 65 standard chemotherapy regimens 65 metastatic CRC 65 Genasense 65 Pivotal Phase III 65 erlotinib Tarceva 65 TroVax ® 65 dose cohort 65 Phase 2a clinical 65 JAK inhibitors 65 FOLOTYN ® 65 romiplostim 65 paclitaxel carboplatin 65 AVOREN 65 chronic lymphocytic leukemia CLL 65 refractory chronic lymphocytic 65 Xcytrin 65 virus HCV protease inhibitor 65 Omacetaxine 65 chlorambucil 65 pancreatic neuroendocrine tumors 65 VEGF Trap 65 CLORETAZINE TM VNP#M 65 Genasense ® 65 bicifadine 65 ENMD # 65 Sutent 65 ularitide 65 FOLFOX6 chemotherapy regimen 65 Laquinimod 65 fostamatinib 65 FOLFOX4 65 RoACTEMRA 65 pain palliation 65 prostate cancer CRPC 65 MERLIN TIMI 65 Phase #b/#a 65 stage IIIB 65 eribulin mesylate 65 Phase IIa trials 65 lomitapide 65 BZL# 65 SUTENT ® 65 Rasilez Tekturna 65 PROMACTA 65 picoplatin 65 Campath alemtuzumab 65 castration resistant prostate cancer 65 LY# [003] 65 chemoradiotherapy 65 ruboxistaurin 65 Octreolin 65 CANCIDAS 65 TRISENOX 65 VNP#M 65 leukemia AML 65 superficial bladder cancer 65 mTOR inhibitors 65 recurrent GBM 65 bevacizumab Avastin ® 65 Phase IIb clinical trials 65 lymphoid malignancies 65 rindopepimut 65 ACZ# 65 CLL8 65 Ocrelizumab 65 vosaroxin 65 farletuzumab 65 cisplatin vinorelbine 65 PLX# 65 goserelin 65 orBec 65 Pixantrone 65 Abiraterone acetate 65 resistant ovarian cancer 65 MetMAb 65 ImClone Erbitux 65 pralatrexate 65 Troxatyl 65 Tocosol Paclitaxel 65 Ambrisentan 65 pradefovir 65 TRO# 65 oral picoplatin 65 INCB# [002] 65 Afatinib 65 lymphoma CTCL 65 XELOX 65 CRLX# 65 Phase IIIb study 65 CTAP# Capsules 65 bortezomib Velcade ® 65 phase 2a 65 adecatumumab MT# 65 Taxotere docetaxel 65 Panzem 65 pan HDAC inhibitor 65 Omnitarg 65 Vectibix panitumumab 65 metastatic malignant 65 Teriflunomide 65 relapsed refractory 65 MEK inhibitor 65 STRIDE PD 65 histone deacetylase HDAC inhibitor 65 hormone refractory prostate cancer 65 alemtuzumab Campath 65 Insegia 65 lasofoxifene 65 cisplatin chemotherapy 65 TOLAMBA 65 advanced hepatocellular carcinoma 65 Phase 1b clinical trials 65 xenograft models 65 assessing T DM1 65 EOquin 65 trabedersen 65 Temsirolimus 65 laquinimod 65 Mylotarg 65 TEMODAL 65 Brentuximab Vedotin SGN 65 stage IIIB IV 65 investigational compounds 65 anticancer compound 65 Panitumumab 65 Voreloxin 65 AQ4N 64 Gattex 64 CCX# 64 plus gemcitabine 64 PKC# 64 bortezomib 64 VIDAZA 64 dexpramipexole 64 LymphoStat B TM 64 gemcitabine cisplatin 64 immunomodulatory therapy 64 Sanofi Aventis Taxotere 64 tofacitinib 64 dosing cohort 64 cetuximab Erbitux R 64 trastuzumab 64 anti angiogenic agents 64 Cotara 64 Allovectin 7 64 DU #b 64 temozolomide 64 MyVax personalized immunotherapy 64 preclinical efficacy 64 HCD# [002] 64 anticancer therapy 64 FOLOTYN 64 Romiplostim 64 Rebif ® 64 PDE4 inhibitor 64 AZILECT ® 64 FOLFIRI chemotherapy 64 Aurora kinase 64 KRAS mutations occur 64 NEVO ™ 64 BCIRG 64 dexanabinol 64 R#/MEM # 64 Lenocta 64 medullary thyroid cancer 64 tezampanel NGX# 64 lenalidomide Revlimid 64 nitazoxanide 64 Xeloda ® 64 adjuvant colon cancer 64 TKI therapy 64 Pertuzumab 64 plus prednisone 64 LymphoStat B belimumab 64 volociximab 64 Sapacitabine 64 Safinamide 64 Telatinib 64 Daclizumab 64 ORAL Sync 64 pegylated interferon alpha 64 neurologic progression 64 MyVax R 64 NSCLC 64 oblimersen 64 Annamycin 64 ADVEXIN 64 Hepatocellular Carcinoma HCC 64 aleglitazar 64 IIa trial 64 ocular formulation 64 refractory gout 64 Pirfenidone 64 mitoxantrone plus 64 NO# [002] 64 fluvastatin 64 gemcitabine 64 APTIVUS 64 SUCCEED trial 64 neoadjuvant treatment 64 docetaxel 64 ARRY 64 elesclomol 64 orally bioavailable 64 DEB# 64 nonsmall cell lung cancer 64 Romidepsin 64 baminercept 64 Neulasta ® 64 palifosfamide 64 SU# [003] 64 PRX # 64 Vidaza azacitidine 64 Vidofludimus 64 MEK inhibitors 64 tasocitinib 64 aclidinium bromide 64 Zactima 64 R sorafenib tablets 64 Combination REOLYSIN R 64 HCV protease inhibitor 64 Ceflatonin R 64 Hycamtin 64 YERVOY 64 Irinotecan 64 TNFerade 64 velafermin belinostat 64 dasatinib Sprycel ® 64 Muraglitazar 64 Tezampanel 64 CYT# potent vascular disrupting 64 PEG PAL 64 corticosteroid dexamethasone 64 PROSTVAC ® 64 milatuzumab 64 NATRECOR R 64 DASISION 64 Trastuzumab 64 methylnaltrexone 64 Pixuvri 64 Acapodene 64 omacetaxine 64 tubulin inhibitor 64 GLYX 64 OncoVex 64 Triolex 64 relapsing multiple sclerosis 64 adalimumab Humira 64 INC# 64 Panzem R 64 selective modulator 64 Xinlay 64 Folfox 64 relapsing remitting multiple sclerosis 64 topotecan 64 TRIOLEX 64 dasatinib 64 free survival PFS 64 ritonavir boosted 64 rituximab Rituxan 64 Betaferon ® 64 Phase IIb clinical 64 leukemia CLL 64 Crizotinib 64 tarenflurbil 64 Amplimexon 64 Alzhemed TM 64 HSP# inhibitor 64 imetelstat 64 ISTODAX 64 pancreatic carcinoma 64 Tykerb lapatinib 64 ThermoDox R 64 Phase IIB 64 viral kinetics 64 esophageal candidiasis 64 Apoptone 64 SCCHN 64 IFN α 64 Lacosamide 64 samalizumab 64 Angiolix 64 Herceptin trastuzumab 64 OMAPRO 64 imatinib therapy 64 safinamide 64 everolimus 64 CINTREDEKIN BESUDOTOX 64 CALGB # [002] 64 pharmacodynamic properties 64 ADAGIO study 64 paclitaxel Taxol 64 CEQ# 64 alkylating agent 64 GRN#L 64 seliciclib CYC# 64 NovoTTF 64 Epratuzumab 64 KRN# 64 VEGF inhibitor 64 PegIntron 64 telcagepant 64 Tarceva 64 Tykerb 64 ThermoDox 64 INSPIRE Trial Phase III 64 sunitinib Sutent ® 64 arzoxifene 64 mCRC 64 ELND# 64 NSABP C 64 phase Ib clinical 64 Campath ® 64 Bevacizumab 64 phase IIIb 64 Alimta pemetrexed 64 CYT# 64 tezampanel 64 NV1FGF 64 placebo controlled Phase III 64 Bronchitol 64 Boceprevir 64 cetuximab 64 Aurexis 64 systemically administered 64 azilsartan medoxomil 64 dimebon 64 dose escalation 64 midstage studies 63 antibody MAb 63 TO AVOID PREGNANCY WHILE 63 gamma secretase inhibitor 63 diabetic neuropathic pain 63 Azacitidine 63 thymalfasin 63 Symadex 63 cannabinor 63 GSK# [002] 63 dalbavancin 63 androgen independent 63 FOLFOX 63 non squamous NSCLC 63 Phase IIa clinical 63 nonclinical studies 63 TASKi2 63 gemcitabine Gemzar R 63 safety tolerability pharmacokinetic 63 mg kg dose 63 refractory metastatic colorectal cancer 63 ABSORB trial 63 OncoVEX 63 L MTP PE 63 Fludara ® 63 alvimopan 63 ALK inhibitor 63 monotherapy 63 REOLYSIN ® 63 castrate resistant prostate cancer 63 nucleoside analog 63 ORENCIA R 63 mTOR inhibition 63 Afinitor 63 MyVax 63 anti EGFR antibody 63 Neoadjuvant 63 aclidinium 63 Dendreon Provenge 63 Merck KGaA Erbitux 63 multiple myeloma MM 63 preclinically 63 Aurora kinase inhibitor 63 cutaneous T cell 63 aflibercept VEGF Trap 63 Yervoy 63 lesinurad 63 ambrisentan 63 Deforolimus 63 novel oral anticoagulant 63 tumor xenograft models 63 multi kinase inhibitor 63 DAPT 63 cetuximab Erbitux ® 63 SABCS 63 eritoran 63 randomized controlled Phase 63 Darusentan 63 confirmatory Phase III 63 tolevamer 63 CALGB 63 lixisenatide 63 HER2 positive breast cancer 63 PDX pralatrexate 63 PD LID 63 rFIXFc 63 Phase III randomized controlled 63 Actemra 63 AVE# 63 ancrod 63 olmesartan 63 recurrent malignant glioma 63 tramiprosate Alzhemed TM 63 initiate Phase 1b 63 recurrent metastatic 63 AZILECT R 63 SRT# [003] 63 novel VDA molecule 63 metastatic colorectal 63 Gleevec imatinib 63 Lenalidomide 63 gemcitabine Gemzar ® 63 NGX# 63 Triapine 63 LBH# 63 satraplatin 63 CLARITY study 63 Taxol paclitaxel 63 receptor inhibitor 63 oral Hycamtin 63 OMP #M# 63 belinostat 63 Denufosol 63 Pfizer Sutent 63 Xeloda capecitabine 63 Pivotal Trial 63 Hsp# Inhibitor 63 metastatic melanoma 63 vinorelbine 63 SinuNase 63 gastrointestinal stromal tumors GIST 63 peginterferon alpha 2a 63 investigational hepatitis C 63 Tarvacin 63 muraglitazar 63 taxane refractory 63 AZD# 63 Gemcitabine 63 CaPre TM 63 #D#C# 63 investigational monoclonal antibody 63 Revlimid 63 denufosol 63 Civacir 63 Nicole Onetto MD 63 trastuzumab Herceptin ® 63 cobiprostone 63 Trofex 63 biliary tract cancer 63 albinterferon alfa 2b 63 dasatinib Sprycel 63 liver metastases 63 S/GSK# 63 Dapagliflozin 63 blinded randomized placebo controlled 63 novel histone deacetylase 63 PF # [002] 63 evaluating REVLIMID 63 cladribine 63 Sandostatin LAR Depot 63 estramustine 63 Tesmilifene 63 brivanib 63 advanced carcinoid 63 glatiramer acetate 63 Cimzia TM 63 tolerability profile 63 Pivotal Phase 63 Evoltra ® 63 Elotuzumab 63 teplizumab 63 R roscovitine 63 lenalidomide Revlimid R 63 tolerability profiles 63 GV# [001] 63 trastuzumab Herceptin 63 pancreatic NET 63 TBC# 63 BENLYSTA ® 63 Natalizumab 63 JAK2 inhibitor 63 solid tumors 63 Catena ® 63 ENMD 63 Bortezomib 63 REVLIMID 63 trodusquemine 63 davunetide intranasal AL 63 stated Michelle Berrey 63 DPP4 inhibitor 63 BR.# 63 Sutent sunitinib 63 confirmatory clinical 63 oral Xeloda 63 MOZOBIL 63 sorafenib Nexavar R 63 GAP #B# 63 BNC# 63 MNTX 63 infusional 5-FU/LV 63 Vilazodone 63 EGFR TKI 63 GRN# 63 pediatric acute lymphoblastic 63 Phase 2b 63 heterozygous FH 63 recurrent ovarian cancer 63 Phase III clinical 63 Clolar ® 63 gefitinib 63 Zarnestra 63 Neupogen ® 63 5 fluorouracil leucovorin 63 evaluating satraplatin 63 Phase 2b clinical trials 63 ThermoDox ® clinical 63 Serdaxin 63 Alfimeprase 63 Relovair 63 ACTEMRA 63 SNT-MC#/idebenone 63 Hodgkin lymphoma HL 63 relapsing MS 63 Actilon 63 CAMMS# 63 dacarbazine chemotherapy 63 refractory metastatic 63 masitinib 63 Orathecin 63 Cetuximab Erbitux 63 IGF 1R inhibitor 63 Diamyd ® 63 Saxagliptin 63 efaproxiral 63 CIMZIA TM certolizumab pegol 63 antitumor effects 63 Everolimus 63 Celgene Revlimid 63 EndoTAG